|
|
|
| Is Your Early-Stage CGT Supply Chain Ready for Late-Stage Scale Up? | As cell and gene therapies advance toward commercialization, scalable supply chains are critical to reaching patients reliably. On November 12, 2026 at 11 AM ET join Cell & Gene Live’s Erin Harris with Lineage Cell Therapeutics CEO Brian Culley and Allogene CTO Ben Beneski to explore cryopreservation, materials planning, inventory visibility, predictive analytics, chain-of-identity, and digital infrastructure. Register now for insights on building resilient, launch-ready operations. |
|
|
|
|
By Siddharth Krishnan | When analytical capability and process understanding fail to keep pace with a drug candidate, the technical uncertainty creates debt that's difficult to pay down. | |
|
|
|
|
| The Adenovirus Revolution In Cancer Treatment | Article | 3PBIOVIAN | Adenoviruses are being reimagined as powerful tools for oncolytic cancer therapy, using their immunogenicity, tumor selectivity, and synergy with immunotherapy to drive new clinical progress. |
|
|
| Challenges And Opportunities With Novel AAV Capsids | Webinar | Viralgen | Explore challenges and solutions in developing novel AAV capsids, focusing on manufacturing complexity, analytical testing, and regulatory considerations for advancing gene therapy effectiveness. |
|
|
| Targeted Gene Insertion Needs More Than One Tool | Article | By David Wiley, ElevateBio | Targeted large gene insertion depends on matching the right mechanism to the biology. Engineered enzymes, recombinases, and retrotransposons help optimize efficiency and precision. |
|
|
| Efficient Plasmid Linearization: Type I & II Enzymes | Poster | By Charlie Fan, Delicia Henriques, Ph.D., Justin Chen, et al., ProBio | Advanced plasmid linearization improves transfection efficiency and gene expression, delivering high-purity DNA with rapid turnaround, low endotoxin, and scalable processes for cell and gene therapy applications. |
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
